Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Other operating expenses

Other operating expenses at other companies

Arvinas logo
ArvinasARVN
$79.4M-32.4%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$140.61M+46.4%
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$58.1M+49.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
$43.58M+49.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$59.65M+26.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$82.77M+31.2%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
Operating expenses:
Research and development87,65378,096171,789147,759
General and administrative15,59414,28230,20525,936
Total operating expenses103,24792,378201,994173,695
Loss from operations(94,204)(48,322)(186,699)(111,186)
Interest and other income, net4,3985,6189,71912,131
Loss before income taxes(89,806)(42,704)(176,980)(99,055)
Provision for (benefit from) income taxes(271)760(271)760

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s other operating expenses?
Nurix Therapeutics, Inc. (NRIX) reported other operating expenses of $103.25M in Q1 2026.
How has Nurix Therapeutics, Inc.'s other operating expenses changed year-over-year?
Nurix Therapeutics, Inc.'s other operating expenses increased by 11.8% year-over-year, from $92.38M to $103.25M.
What is the long-term trend for Nurix Therapeutics, Inc.'s other operating expenses?
Over 4 years (2021 to 2025), Nurix Therapeutics, Inc.'s other operating expenses has grown at a 25.8% compound annual growth rate (CAGR), from $147.64M to $369.65M.
What does other operating expenses mean?
Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.

Ask your AI about Nurix Therapeutics, Inc.'s other operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude